The aim of this study was to investigate the impact of genetic polymorphisms in the metabolic and cellular transport pathway of methotrexate (MTX) on the clinical outcome of MTX monotherapy in Japanese rheumatoid arthritis (RA) patients. Fifty-five patients were treated with MTX monotherapy at a dose of 410 mg/week. The total concentration of MTX-polyglutamates (MTX-PGs) was measured at steady-state in red blood cells (RBCs) by high performance liquid chromatography. The genotype at 16 polymorphic sites in 11 genes (ABCB1, ABCG2, ABCC2, RFC1, PCFT, SLCO1B1, MTHFR, GGH, ATIC, MTR, and MTRR) was analyzed. No significant association between the total concentration of MTX-PGs in RBCs and clinical outcome was found. However, patients with the ABCB1 3435TT genotype had a significantly lower mean disease activity score (DAS) 28 than did patients with the ABCB1 3435CC genotype (p = 0.02). Similarly, patients with the ABCB1 2677AA/AT/TT genotypes had a significantly lower mean DAS28 than did patients with the ABCB1 2677GG/GA/GT genotypes (p = 0.04). The patients with the MTHFR 1298AA genotype had a significantly lower mean DAS28 than those with the MTHFR 1298AC/CC genotypes (p = 0.04). In conclusion, the ABCB1 3435C>T, ABCB1 2677G>A/T, and MTHFR 1298A>C polymorphisms influenced the efficacy of MTX monotherapy.
Introduction
Methotrexate ¤MTX¥ is currently a widely prescribed disease-modifying antirheumatic drug ¤DMARD¥ for the treatment of rheumatoid arthritis ¤RA¥, and MTX is regarded as a key drug for the management of RA. 1¥ In Japan, low-dose MTX, usually administered orally as a weekly pulse, is commonly used to treat RA that is unresponsive to non-steroidal anti-inflammatory drugs ¤NSAIDs¥. The clinical response to low-dose MTX varies widely between patients, 2,3¥ and the factors that contribute to this variability remain unclear. The inter-patient variability is thought to be correlated with intracellular concentrations of MTX-polyglutamates ¤MTX-PGs¥, 4,5¥ individual differences in a variety of enzyme and transporter activities that are related to the response to MTX, 5®8¥ and other patient-related factors such as body surface area ¤BSA¥, renal function, and disease severity.
P-glycoprotein ¤P-gp, gene name ABCB1¥, which plays an important role in the export of many drugs and the acquisition of drug resistance, recognizes MTX as a substrate. 9¥ Some studies indicate that ABCB1 polymorphisms are associated with clinical responses to MTX, 7,10®12¥ but most of these studies included patients treated with a combination of MTX and one or more other DMARDs. Therefore, we chose to analyze patients receiving MTX monotherapy in order to evaluate clinical responses specific to MTX.
Multiple transporters and enzymes were found to participate in the metabolism and transporting of MTX.
9,13,14¥ Reduced folate carrier ¤RFC¥ 1 mediates most intestinal absorption of MTX and uptake to target cells, but proton-coupled folate transporter ¤PCFT¥ and organic anion transporting-polypeptide ¤OATP¥ 1B1 ¤gene name SLCO1B1¥ also mediate these processes to a lesser extent. After absorption into the body and entering circulation, MTX is rapidly converted to MTX-PGs by folylpolyglutamate synthetase ¤FPGS¥, which adds up to six sequential glutamyl residues to MTX. 9¥ MTX-PGs directly inhibit aminoimidazole carboxamide ribonucleotide transformylase ¤ATIC¥ and affect several enzymes in the folate metabolic pathway, including 5,10-methylenetetrahydrofolate reductase ¤MTHFR¥, methionine synthase ¤MTR¥, and methionine synthase reductase ¤MTRR¥. È-Glutamyl hydrolase ¤GGH¥ is a lysosomal peptidase that catalyses the removal of È-linked polyglutamates, converting long-chain MTX-PGs into shortchain MTX-PGs and ultimately to MTX, allowing folate to be exported from the cell.
15,16¥ Moreover, MTX is exported from the cells by ATP binding cassette ¤ABC¥ transporters, including P-gp, breast cancer resistance protein ¤BCRP, gene name ABCG2¥, and multidrug resistance-associated protein 2 ¤MRP2, gene name ABCC2¥.
MTX cannot be detected in plasma because more than 95% of the MTX administered at a low-dose is metabolized within 24 h after administration. 17¥ While there is little value in monitoring low-dose MTX therapy using plasma concentrations, MTX is converted to MTX-PGs by FPGS in cells, and MTX-PGs accumulate in red blood cells ¤RBCs¥. 14,18,19¥ As the concentration of MTX-PGs in RBCs is reported to reflect the concentration of MTX-PGs in target cells ¤mononuclear cells, lymphocytes, or synovial cells¥, 4¥ the concentration of MTX-PGs in RBCs is used as a substitute for the concentration of MTX-PGs in target cells. Therefore, we hypothesized that the concentration of MTX-PGs in RBCs may be valuable as an indicator of the response to MTX treatment. Since it is difficult to measure individual MTX-PGs clinically, we measured the total concentration of MTX-PGs after conversion to MTX.
The purpose of this study was to investigate the influence of genetic polymorphisms of transporters and metabolic enzymes in the metabolic and cellular transport pathway of MTX on the efficacy of MTX monotherapy in Japanese patients.
Methods

Patients:
The study was a retrospective study in Japanese patients with RA who were naive to MTX treatment. Between October 1998 and May 2008, 150 patients were diagnosed with RA from the Department of Rheumatology, Kumamoto Saishunso National Hospital, and 71 patients were treated with MTX monotherapy. Sixteen patients were excluded because they proved poor compliance for MTX treatment. Therefore, we recruited 55 patients into our study. RA was diagnosed according to American College of Rheumatology criteria. 20¥ All patients were receiving a weekly pulse of MTX ¤oral administration 3 times every 12 h¥. Any patient receiving biopharmaceutical therapy or another DMARD concomitantly during the 2-month period prior to enrollment in the study was excluded from the study. MTX treatment had been started at initial doses of 2 mg to 10 mg per week. Thereafter, the dose of MTX had been maintained or increased according to the physicianös decisions. Usually, the dosage had been raised when the effect of MTX was not sufficient, as judged by the clinical response. All patients received folic acid ¤5®10 mg/week¥ to prevent adverse effects induced by MTX. For the present analysis, clinical data from the first 6 months of follow up were defined. Response to MTX was evaluated according to the American College of Rheumatology criteria. 20¥ Disease activity score ¤DAS¥ 28, C-reactive protein ¤CRP¥, erythrocyte sedimentation rate ¤ESR¥, mean corpuscular volume ¤MCV¥, and serum creatinine clearance ¤sCr¥ were recorded on day 0 and at 3 months after initiation of MTX therapy. Adverse events of MTX were recorded at the time of a patientös visit during treatment.
The Disease Activity Score in 28 joints ¤DAS28¥ was calculated as follows using the tender joint count ¤maximum 28¥, swollen joint count ¤maximum 28¥, CRP level ¤in mg/L¥, and the patientös assessment of disease activity:
14 ' ¤patientös assessment of disease activity¥ ¦ 0.96.
Data on age, sex, body weight, body height, date at which MTX administration was initiated, and clinical and laboratory results ¤i.e., DAS28, CRP, ESR, MCV, and sCr¥ were obtained from the medical records of each patient. This study was approved by the Ethics Committee of Kumamoto Saishunso National Hospital and Kumamoto University. After receiving a detailed briefing on the purpose and protocol of the study, each patient gave written informed consent.
Determination of total concentration of MTXPGs in RBCs:
Total concentrations of MTX-PGs in RBCs were measured after conversion to MTX by high performance liquid chromatography ¤HPLC¥ as described previously. 22¥ In brief, to determine the total concentration of MTX-PGs in RBCs, samples ¤5 mL¥ of heparinized peripheral whole blood were collected from RA patients who achieved a steady-state in the concentration of MTX-PGs in RBCs ¤concentration of MTX-PGs in RBCs reached a steady-state at 6®8 weeks 23¥ ¥ 5 days after MTX administration. All collected blood samples were stored immediately at 4ôC, and RBCs and plasma were separated within 24 h. RBCs were cryopreserved until analysis. RBC samples were thawed at room temperature, and 150 µL of buffer containing 100 mmol/L potassium phosphate and 150 mmol/L mercaptoethanol was added to each sample. Samples were incubated for 18 h in the dark at 37ôC. After incubation, we added 25 µL of perchloric acid to the mixture, which was then vortex-mixed and centrifuged it at 3,000 ' g for 5 min. A sample of the supernatant ¤100 µL¥ was injected into the HPLC system. The chromatographic separation was performed on an Inertsil ODS, 4.6 ' 150 mm C18 column ¤2.5 mm particle size; GL Sciences¥. The mobile phase consisting of 6.25 g/L phosphate buffer ¤adjusted to pH 3.0 with phosphoric acid¥ and acetonitrile in a 89.7% to 10.3% ratio was introduced at a flow rate of 1 mL/min. The MTX product was measured at 303 nm.
Genotyping: DNA was extracted using the MagNa Pure LC DNA Isolation Kit I ¤Roche Diagnostics, Tokyo, Japan¥ from peripheral blood samples taken from each patient. Genotyping was performed using TaqMan SNP genotyping assays ¤Applied Biosystems, Foster City, USA¥, polymerase chain reaction®restriction fragment length polymorphism ¤PCR-RFLP¥, or direct sequencing, depending on the particular polymorphic site. TaqMan assay IDs used for genotyping are listed in Table 1 . To determine the genotype at the RFC1 80AhG polymorphism, the region encompassing the A80G polymorphic site was amplified ¤forward primer: 5$-AGCGGTGGAGAAGCAGGT-3$, reverse primer: 5$-GGAGGTAGGGGGTGATGAAG-3$¥, and the PCR products were digested with HhaI ¤New England BioLabs, Tokyo, Japan¥ as previously described. 24¥ To determine the genotype at the ABCB1 2677GhA/T polymorphism, the region encompassing the 2677GhA/T polymorphic site was amplified by PCR ¤forward primer: 5$-TCTTAGCAATTGTACCCATCATTG-3$, reverse primer: 5$-CAGGTTCTTGACCGAAACGA-3$¥, and the resulting PCR products were analyzed by direct sequencing.
Statistical analysis:
Relationships between the total concentration of MTX-PGs and each clinical parameter were analyzed using correlation analysis. Relationships between two groups were analyzed using Studentös t test or the nonparametric Mann-Whitney test. Relationships between three groups were analyzed using one-factor analysis of variance ¤ANOVA¥ or the Kruskal-Wallis test. Relationships between genotypes, hepatotoxicity, and nephrotoxicity were analyzed using 2 ' 2 cross-tabulations or m ' n cross-tabulations. A p-value of less than 0.05 was considered to represent a statistically significant difference.
Results
Patients: Characteristics of the group of 55 RA patients ¤11 male and 44 female¥ enrolled in this study are presented in Table 2 . These patients did not receive biopharmaceutical therapy prior to or during this study. All patients had received folic acid ¤5 mg/week¥ from the initiation of MTX therapy and continued to receive it throughout the study period. The median patient age was 59 years, and the mean MTX dose was 7.2 mg/week. All patients had normal liver function before treatment; however, hepatotoxicity was observed in 9 of 55 patients during the evaluation period. A temporary elevation in creatinine to levels above the upper normal limit was observed in three patients, but they each continued to receive MTX treatment and to participate in the study.
Relationship between total concentration of MTX-PGs and MTX efficacy and toxicity:
The relationship between MTX dose and total concentration of MTX-PGs is shown in Figure 1 . A total of 108 samples were collected ¤1®7 samples per patient¥ and the mean total concentration of MTX-PGs was used to represent patients that gave more than one sample. The total concentration of MTX-PGs ¤mean + SD¥ in RBCs was 0.11 + 0.07 µg/mL ¤range 0.03®0.35 µg/mL¥. Based on the correlation analysis, there was no significant association between the total concentration of MTX-PGs in RBCs and any of the clinical parameters evaluated ¤DAS28, CRP, ESR, MCV, SCr¥ ¤Fig. 2¥.
Associations between genetic polymorphisms and total concentration of MTX-PGs in RBCs:
The frequencies of each genotype at the 16 polymorphic sites in enrolled patients are presented in Table 3 . Patients with the MTR 2756GG genotype had a significantly higher median total concentration of MTX-PGs in RBCs than did the patients with the MTR 2756AG genotype ¤p © 0.01, the non-parametric Mann-Whitney test¥ ¤Table 3¥. However, based on the non-parametric Mann-Whitney test or KruskalWallis test, no significant association was observed between the total concentration of MTX-PGs and any other polymorphisms ¤ABCB1, ABCG2, ABCC2, RFC1, PCFT, SLCO1B1, GGH, MTHFR, ATIC, or MTRR¥.
Effects of genetic polymorphisms on MTX efficacy:
Based on the Kruskal-Wallis test, patients with the ABCB1 3435TT genotype had a significantly lower mean DAS28 than patients with the ABCB1 3435CC genotype ¤p © 0.02, Fig. 3B¥ . Similarly, based on the one-factor ANOVA, patients with the ABCB1 2677AA/AT/ TT genotypes had a significantly lower mean DAS28 than patients with the ABCB1 2677GG/GA/GT genotypes ¤p © 0.04, Fig. 3A¥ . In contrast, no significant differences in mean DAS28 were observed between patients with different genotypes at the ABCB1 1236ChT polymorphism. The patients with the MTHFR 1298AA genotype had a significantly lower mean DAS28 than those with the MTHFR 1298AC/CC genotypes ¤p © 0.04, Studentös t test; Fig. 3C¥ . There was no association between DAS28 and genotype at any other polymorphic site in eight genes ¤ABCG2, ABCC2, RFC1, PCFT, SLCO1B1, GGH, ATIC, or MTRR¥ ¤Table 3¥.
Discussion
In this study, we evaluated the relationship between the clinical response to MTX monotherapy in 55 Japanese RA patients and genetic variations in genes encoding transporters and metabolic enzymes in the metabolic and cellular transport pathway of MTX. MTX is often used concomitantly with other DMARDs; therefore, it is difficult to Continued on next page:
assess the efficacy of MTX. We excluded the patients receiving biopharmaceutical therapy or other DMARDs concomitantly because this study was designed to evaluate the action of MTX monotherapy. Our results indicated that patients with the ABCB1 3435TT, ABCB1 2677AA/AT/TT, and MTHFR 1298AA genotypes had better outcomes with MTX monotherapy than did the patients with other genotypes at these sites.
MTX cannot be detected in plasma because more than 95% of the MTX administered at a low-dose is metabolized within 24 h after administration. 17¥ However, MTX is converted to MTX-PGs by FPGS in cells, and MTX-PGs accumulate in RBCs.
14,18,19¥ Therefore, we assumed that the concentration of MTX-PGs in RBCs might be valuable as an indicator of clinical response to MTX monotherapy. Unexpectedly, total concentration of MTX-PGs in RBCs did not increase in a dose-dependent manner, and no association between total concentration of MTX-PGs in RBCs and DAS28, ESR, CRP, MCV, hepatotoxicity or nephrotoxicity was observed. In the USA and European countries, the recommended target dose of MTX is 15®20 mg/week, but the approved maximum dose of MTX in Japan is 8 mg/week. In fact, the patients enrolled in our study receive an MTX dose of 4, 6, 8, or 10 mg/week ¤mean + SD, 7.2 + 1.2 mg/ week¥, and based on the Kruskal-Wallis test, there was no difference in mean total concentration of MTX-PGs in RBCs between patients receiving different doses ¤Fig. 1¥.
ABCB1 2677GhA/T and 3435ChT did not influence total MTX concentration in RBCs, but significantly affected the DAS28 score. Because ABCB1 2677 and 3435 variants reduced its expression or efflux-transporting activity in target cells, these gene variants might be associated with favorable clinical outcomes. In fact, a few studies indicate that some ABCB1 variants correlate with the efficacy and toxicity of MTX in RA patients.
7,10®12¥ Previous reports suggest that the ABCB1 T allele of the 3435ChT polymorphism was associated with MTX sensitivity.
10, 12¥ The results of this study were consistent with these reports; in addition, our results indicated that the T and A alleles of the ABCB1 2677GhA/T polymorphism were associated with higher efficacy of MTX monotherapy. Collectively, these results suggest that some ABCB1 variants may potentiate the effect of low-dose MTX in patients with RA.
Genotype at the MTHFR 1298AhC polymorphic site also influenced DAS28. The influence of MTHFR 1298AhC on the response to MTX treatment has been studied repeatedly, 6,8,11,25®29¥ and our results were consistent with previous findings, 28¥ in that patients with the MTHFR 1298AA genotype had a lower mean DAS28 than did carriers of the MTHFR 1298C allele. There are few reports on the relationship between MTR polymorphisms and MTX response. 30¥ We found that patients with the GG genotype at MTR 2756 had significantly higher total concentration of MTX-PGs in RBCs ¤p © 0.01, Table 3¥ and significantly lower serum CRP level ¤p © 0.01¥ than patients with the MTR 2756AG genotype. This result might become relevant to future studies on MTR polymorphisms and clinical responses to MTX.
In general, it is very difficult to detect a clear association between genetic polymorphisms and clinical outcomes of MTX treatment. We did not check the ABCB1 expression in RBC and target cells; however, it was thought that ABCB1 was expressed in target cells but not RBC. Therefore, ABCB1 polymorphism might influence the clinical response. To our knowledge, the present data are the first to indicate an association between genetic polymorphisms and clinical outcomes in Japanese RA patients treated with MTX monotherapy. However, the number of RA patients enrolled in this study was small, and the mechanism¤s¥ by which of the polymorphisms may influence outcomes remains unclear. MTX has been shown to have multiple mechanisms of action within the folate pathway.
In conclusion, we found that ABCB1 3435ChT, ABCB1 2677GhA/T, and MTHFR 1298AhC polymorphisms influence the efficacy of MTX monotherapy. These polymorphisms may be useful as indicators of the clinical response to MTX treatment in Japanese RA patients. However, further prospective studies with larger sample sizes are required to confirm our observations.
